Summary: There was no association of plasma DPP-4 activity levels with bone mineral density (BMD), body composition, or incident hip fractures in a cohort of elderly community-dwelling adults. Introduction: Dipeptidyl peptidase IV (DPP-4) inactivates several key hormones including those that stimulate postprandial insulin secretion, and DPP-4 inhibitors (gliptins) are approved to treat diabetes. While DPP-4 is known to modulate osteogenesis, the relationship between DPP-4 activity and skeletal health is uncertain. The purpose of the present study was to examine possible associations between DPP-4 activity in elderly subjects enrolled in the Cardiovascular Health Study (CHS) and BMD, body composition measurements, and incident hip fractures. Methods: All 1536 male and female CHS participants who had evaluable DXA scans and plasma for DPP-4 activity were included in the analyses. The association between (1) BMD of the total hip, femoral neck, lumbar spine, and total body; (2) body composition measurements (% lean, % fat, and total body mass); and (3) incident hip fractures and plasma levels of DPP-4 activity were determined. Results: Mean plasma levels of DPP-4 activity were significantly higher in blacks (227 ± 78) compared with whites (216 ± 89) (p = 0.04). However, there was no significant association of DPP-4 activity with age or gender (p ≥ 0.14 for both). In multivariable adjusted models, there was no association of plasma DPP-4 activity with BMD overall (p ≥ 0.55 for all) or in gender stratified analyses (p ≥ 0.23). There was also no association of DPP-4 levels and incident hip fractures overall (p ≥ 0.24) or in gender stratified analyses (p ≥ 0.39). Conclusion: Plasma DPP-4 activity, within the endogenous physiological range, was significantly associated with race, but not with BMD, body composition, or incident hip fractures in elderly community-dwelling subjects.
Bibliographical noteFunding Information:
This work was supported by the National Institutes of Health (NIH) for the Cardiovascular Health Study (CHS) components (LDC, PB, HAF, and JAR) by the National Heart, Lung, and Blood Institute (NHLBI) with additional contribution from the National Institute of Neurological Disorders and Stroke (contracts HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC55222N01HC85080, N01HC85081, N01HC85082, N01HC85083, and N01HC85086 and grants HL094555 and 080295); additional support provided by the National Institute on Aging (NIA) (RO1AG023629 (CHS?LDC, PB, HAF, and JAR), P01 AG036675?CMI, WDH), and Augusta University Pilot Study Research Program (WDH/LC) and supported in part by the Department of Veterans Affairs (Merit Award 1I01CX000930-01?WDH). The contents of this publication do not represent the views of the Department of Veterans Affairs or the United States Government.
© 2017, International Osteoporosis Foundation and National Osteoporosis Foundation.
Copyright 2017 Elsevier B.V., All rights reserved.
- Body composition
- Bone mineral density
- Dipeptidyl peptidase IV